Mon - Sat 8:00 - 6:30, Sunday - CLOSED
Generic drug entry tends to signal the end of an era — patents expire, competitors reach settlements and prices are cut.
The storyline tends to play out in mostly the same way: patents and exclusivity protections eventually expire, competition swoops in, and within a few months, they’ve transformed the market into a new, less expensive and less marketed landscape.
At least that’s the theory. The reality isn’t always that simple.
Unlock this story instantly and join 133,000+ biopharma pros reading Endpoints daily — and it's free.